[SARS-Cov-2 vaccine's acceptance among pregnant women-A cross-sectional survey].
Acceptabilité du vaccin-Sars CoV-2 chez les femmes enceintes, une enquête transversale par questionnaire.
Grossesse
Pregnancy
SARS-CoV-2
SARS-Cov-2
Vaccin
Vaccine
Journal
Gynecologie, obstetrique, fertilite & senologie
ISSN: 2468-7189
Titre abrégé: Gynecol Obstet Fertil Senol
Pays: France
ID NLM: 101693805
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
08
04
2022
revised:
11
07
2022
accepted:
12
07
2022
medline:
23
10
2023
pubmed:
2
8
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
SARS-CoV-2 is more likely to cause severe cases in pregnant women. They were part of the priority groups since April 2021 to benefit from SARS-CoV-2 vaccination before its extent to general population. This contribution aims to evaluate, in the postpartum period, the achievement of COVID-19 vaccination and factors associated in women during their pregnancy. Multicenter cross-sectional survey study conducted from September to December 2021 with online self-questionnaire. All postpartum patients hospitalized in one of the 6 participating maternity hospitals were invited to answer. The questionnaire asked patients about their demographic characteristics, vaccination modalities, vaccine tolerance, and their general perception of vaccination. Of the 371 women who responded, the vaccination rate was 65.7% (IC95% [60.8-70.4]), whom 98.8% entirely during pregnancy. Associated factors with vaccination during pregnancy were older age, higher socio-professional category, and prior information provided by health professionals. Factors that appear to motivate vaccination were personal protection and protection of the newborn. Finally, main factors negatively influencing the vaccination process were the fear of vaccine side effects and the negative perception of vaccines in general. Acceptability and information about the vaccine by health professionals is in constant improvement. Information campaigns should be continued to improve the acceptability of vaccination, in light of the accumulating data.
Identifiants
pubmed: 35914734
pii: S2468-7189(22)00236-7
doi: 10.1016/j.gofs.2022.07.004
pmc: PMC9335352
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Multicenter Study
English Abstract
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
712-720Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2022 Elsevier Masson SAS. All rights reserved.